Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors; Bioorganic & Medicinal Chemistry; Vol. 29, iss. 1

Bibliographic Details
Parent link:Bioorganic & Medicinal Chemistry
Vol. 29, iss. 1.— 2021.— [115836, 17 p.]
Corporate Author: Национальный исследовательский Томский политехнический университет Инженерная школа новых производственных технологий Научно-образовательный центр Н. М. Кижнера
Other Authors: Cantini N. Niccolo, Khlebnikov A. I. Andrey Ivanovich, Crocetti L. Letizia, Shchepyotkin I. A. Igor Aleksandrovich, Floresta G. Giuseppe, Guerrini G. Gabriella, Vergelli C. Claudia, Bartolucci G. Gianluca, Quinn M. Mark, Giovannoni M. P. Maria Paola
Summary:Title screen
Human neutrophil elastase (HNE) is a potent protease that plays an important physiological role in many processes but is also involved in a variety of pathologies that affect the pulmonary system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here a new series of pyrazolopyridine and pyrrolopyridine derivatives as HNE inhibitors designed as modifications of our previously synthesized indazoles and indoles in order to evaluate effects of the change in position of the nitrogen and/or the insertion of an additional nitrogen in the scaffolds on biological activity and chemical stability. We obtained potent HNE inhibitors with IC50 values in the low nanomolar range (10–50 nM), and some compounds exhibited improved chemical stability in phosphate buffer (t1/2 > 6 h). Molecular modeling studies demonstrated that inhibitory activity was strictly dependent on the formation of a Michaelis complex between the OH group of HNE Ser195 and the carbonyl carbon of the inhibitor. Moreover, in silico ADMET calculations predicted that most of the new compounds would be optimally absorbed, distributed, metabolized, and excreted. Thus, these new and potent HNE inhibitors represent novel leads for future therapeutic development.
Режим доступа: по договору с организацией-держателем ресурса
Language:English
Published: 2021
Subjects:
Online Access:https://doi.org/10.1016/j.bmc.2020.115836
Format: MixedMaterials Electronic Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=663930

MARC

LEADER 00000naa0a2200000 4500
001 663930
005 20250429161114.0
035 |a (RuTPU)RU\TPU\network\35100 
035 |a RU\TPU\network\28532 
090 |a 663930 
100 |a 20210318d2021 k||y0rusy50 ba 
101 0 |a eng 
102 |a NL 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors  |f N. Cantini, A. I. Khlebnikov, L. Crocetti [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 59 tit.] 
330 |a Human neutrophil elastase (HNE) is a potent protease that plays an important physiological role in many processes but is also involved in a variety of pathologies that affect the pulmonary system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here a new series of pyrazolopyridine and pyrrolopyridine derivatives as HNE inhibitors designed as modifications of our previously synthesized indazoles and indoles in order to evaluate effects of the change in position of the nitrogen and/or the insertion of an additional nitrogen in the scaffolds on biological activity and chemical stability. We obtained potent HNE inhibitors with IC50 values in the low nanomolar range (10–50 nM), and some compounds exhibited improved chemical stability in phosphate buffer (t1/2 > 6 h). Molecular modeling studies demonstrated that inhibitory activity was strictly dependent on the formation of a Michaelis complex between the OH group of HNE Ser195 and the carbonyl carbon of the inhibitor. Moreover, in silico ADMET calculations predicted that most of the new compounds would be optimally absorbed, distributed, metabolized, and excreted. Thus, these new and potent HNE inhibitors represent novel leads for future therapeutic development. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t Bioorganic & Medicinal Chemistry 
463 |t Vol. 29, iss. 1  |v [115836, 17 p.]  |d 2021 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a human neutrophil elastaseInhibitors 
610 1 |a nitrogen heterocycle 
610 1 |a stability 
610 1 |a ADMET 
610 1 |a molecular docking 
610 1 |a ингибиторы 
610 1 |a молекулярная стыковка 
701 1 |a Cantini  |b N.  |g Niccolo 
701 1 |a Khlebnikov  |b A. I.  |c Chemist  |c Professor of Tomsk Polytechnic University  |f 1963-  |g Andrey Ivanovich  |3 (RuTPU)RU\TPU\pers\33927  |9 17500 
701 1 |a Crocetti  |b L.  |g Letizia 
701 1 |a Shchepyotkin  |b I. A.  |c doctor-biophysicist  |c leading researcher of Tomsk Polytechnic University, candidate of medical science  |f 1962-  |g Igor Aleksandrovich  |3 (RuTPU)RU\TPU\pers\37358 
701 1 |a Floresta  |b G.  |g Giuseppe 
701 1 |a Guerrini  |b G.  |g Gabriella 
701 1 |a Vergelli  |b C.  |g Claudia 
701 1 |a Bartolucci  |b G.  |g Gianluca 
701 1 |a Quinn  |b M.  |g Mark 
701 1 |a Giovannoni  |b M. P.  |g Maria Paola 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа новых производственных технологий  |b Научно-образовательный центр Н. М. Кижнера  |3 (RuTPU)RU\TPU\col\23556 
801 0 |a RU  |b 63413507  |c 20210318  |g RCR 
850 |a 63413507 
856 4 |u https://doi.org/10.1016/j.bmc.2020.115836 
942 |c CF